{"id":62826,"date":"2026-03-21T10:02:20","date_gmt":"2026-03-21T09:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/"},"modified":"2026-03-21T10:02:20","modified_gmt":"2026-03-21T09:02:20","slug":"omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/","title":{"rendered":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd<\/sup> Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled \u201cAdvances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,\u201d<\/i> will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, H\u00f4pital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children\u2019s Healthcare of Atlanta.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe EBMT Annual Meeting is a key event for professionals in transplantation and cellular therapy, bringing together stakeholders from around the world.<\/p>\n

\nAbout Omeros Corporation<\/b><\/p>\n

\nOmeros is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros\u2019 lead lectin pathway inhibitor YARTEMLEA\u00ae <\/sup>(narsoplimab-wuug), which inhibits the pathway\u2019s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros\u2019 long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.<\/p>\n

\nUnder a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros\u2019 pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder that is fully funded by the National Institute on Drug Abuse, as well as a growing portfolio of novel molecular and cellular oncology programs. For more information about Omeros and its programs, visit www.omeros.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Cook Williams
\n
Cook Williams Communications, Inc.
\n
Investor and Media Relations
\n
IR@omeros.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled \u201cAdvances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62826","6":"format-standard","7":"category-industry"},"yoast_head":"\nOmeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled \u201cAdvances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-21T09:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment\",\"datePublished\":\"2026-03-21T09:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/\"},\"wordCount\":349,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260321749459\\\/en\\\/606373\\\/5\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/\",\"name\":\"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260321749459\\\/en\\\/606373\\\/5\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"datePublished\":\"2026-03-21T09:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260321749459\\\/en\\\/606373\\\/5\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260321749459\\\/en\\\/606373\\\/5\\\/Omeros_Logo_RGB_with_R.2014.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled \u201cAdvances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-21T09:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment","datePublished":"2026-03-21T09:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/"},"wordCount":349,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/","url":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/","name":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg","datePublished":"2026-03-21T09:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260321749459\/en\/606373\/5\/Omeros_Logo_RGB_with_R.2014.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62826"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62826\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}